Cytomx Therapeutics Stock In The News

CTMX Stock  USD 0.65  0.06  10.17%   
Our overall analysis of CytomX Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards CytomX Therapeutics. The specific impact of CytomX Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of CytomX Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using CytomX Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out CytomX Therapeutics Backtesting and CytomX Therapeutics Hype Analysis.
For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

CytomX Therapeutics Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
CytomX Therapeutics Announces 2024 Financial Results and Provides Business Update
https://www.globenewswire.com/news-release/2025/03/06/3038628/37704/en/CytomX-Therapeutics-Announces-2024-Financial-Results-and-Provides-Business-Update.html
 Neutral
Macroaxis News: globenewswire.com
CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference
https://www.globenewswire.com/news-release/2025/03/05/3037337/37704/en/CytomX-Therapeutics-to-Present-at-the-Barclays-27th-Annual-Global-Healthcare-Conference.html
 Neutral
Yahoo News
No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
https://finance.yahoo.com/news/no-memes-ma-am-try-102500968.html
 Bullish
Yahoo News
Jasper Therapeutics (JSPR) Surges 110% in a Month: Here's Why
https://finance.yahoo.com/news/jasper-therapeutics-jspr-surges-110-171400796.html
 Neutral
Yahoo News
Travere (TVTX) Stock Up More Than 30% in 3 Months: Here's Why
https://finance.yahoo.com/news/travere-tvtx-stock-more-30-162500526.html
 Bullish
Yahoo News
CytomX Therapeutics Announces FDA Cleara...
https://finance.yahoo.com/news/cytomx-therapeutics-announces-fda-clearance-130000958.html
 Neutral
Yahoo News
Ionis' (IONS) Donidalorsen Meets Late-Stage HAE Study Goal
https://finance.yahoo.com/news/ionis-ions-donidalorsen-meets-stage-182300111.html
 Neutral
Yahoo News
Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why
https://finance.yahoo.com/news/lisata-lsta-stock-more-35-171200177.html
 Bullish
Yahoo News
Mirum (MIRM) Banks on Livmarli Sales Despite Recent Setback
https://finance.yahoo.com/news/mirum-mirm-banks-livmarli-sales-164400692.html
 Bullish
Yahoo News
AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal
https://finance.yahoo.com/news/astrazenecas-azn-imfinzi-combo-meets-194200656.html
 Neutral

CytomX Therapeutics Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide CytomX and other traded companies coverage with news coverage. We help investors stay connected with CytomX headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on CytomX Stock performance. Please note that trading solely based on the CytomX Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.
CytomX Therapeutics' linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help CytomX Therapeutics investors visualize upcoming and past events in order to time the market based on CytomX Therapeutics noise-free hype analysis.
CytomX Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the CytomX earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about CytomX Therapeutics that are available to investors today. That information is available publicly through CytomX media outlets and privately through word of mouth or via CytomX internal channels. However, regardless of the origin, that massive amount of CytomX data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of CytomX Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of CytomX Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to CytomX Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive CytomX Therapeutics alpha.

CytomX Largest EPS Surprises

Earnings surprises can significantly impact CytomX Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-03-11
2023-12-31-0.030.010.04133 
2022-11-08
2022-09-30-0.31-0.35-0.0412 
2021-11-04
2021-09-30-0.31-0.35-0.0412 
2016-11-03
2016-09-30-0.35-0.4-0.0514 
2016-03-07
2015-12-31-0.34-0.39-0.0514 
2024-08-08
2024-06-30-0.14-0.080.0642 
View All Earnings Estimates

CytomX Therapeutics Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to CytomX Therapeutics Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
zacks News
11th of March 2025
CytomX Therapeutics Upgraded to Strong Buy Heres What You Should Know
at zacks.com 
Yahoo News
7th of March 2025
CytomX Therapeutics Inc Q4 2024 Earnings Call Highlights Strategic Advances and ...
at finance.yahoo.com 
Gurufocus Stories at Macroaxis
6th of March 2025
CytomX Therapeutics Announces 2024 Financial Results and Provide
at gurufocus.com 
Yahoo News
5th of March 2025
Acadia Pharmaceuticals Q4 Earnings Lag Estimates
at finance.yahoo.com 
Google News at Macroaxis
28th of February 2025
CytomX Therapeutics Stock Price Crosses Below Fifty Day Moving Average - Time to Sell - Ma...
at news.google.com 
zacks News
26th of February 2025
Acadia Pharmaceuticals Q4 Earnings Lag Estimates
at zacks.com 
Simply Wall St News at Macroaxis
4th of February 2025
CytomX Therapeutics, Inc. Looks Inexpensive After Falling 26 percent But Perhaps Not Attra...
at simplywall.st 
Google News at Macroaxis
29th of January 2025
Shareholders in CytomX Therapeutics are in the red if they invested five years ago - Yahoo...
at news.google.com 
zacks News
10th of January 2025
NTLA Announces Strategic Reorganization Job Cuts in 2025, Stock Down
at zacks.com 
zacks News
17th of December 2024
Merck Ends Development of Two Experimental Cancer Drugs
at zacks.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CytomX Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CytomX Therapeutics' short interest history, or implied volatility extrapolated from CytomX Therapeutics options trading.

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.